Experimental new drug for dilated cardiomyopathy

11th August 2016

An experimental drug designed specifically to treat heart contraction problems in dilated cardiomyopathy (DCM) may begin trials next year, the makers have announced.

The American biopharmaceutical company MyoKardia says it aims to start phase one clinical development of MYK-491 in the first half of 2017.  It says the drug, designed to establish normal heart contractility in inherited dilated cardiomyopathy, is on track for submission to the United States Food and Drug Administration’s investigational new drug programme (IND) to initiate clinical studies.

The IND programme allows pharmaceutical companies permission to send experimental drugs across the states, usually to researchers, before a marketing application for the drug has been approved.

The company is also working on a drug to treat the underlying causes of hypertrophic cardiomyopathy (HCM).  Early trials from this drug, MYK-461, has suggested the drug is well tolerated and has the ability to reduce excessive heart muscle contractility.

MyoKardia says it is using its precision medicine platform to generate a pipeline of therapies for the treatment of the two most common forms of heritable cardiomyopathy—HCM and DCM.